Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections. - Wikidata - wikimedia - TriplyDB

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

http://www.wikidata.org/entity/Q42686004

about

Posaconazole: an oral triazole with an extended spectrum of activity Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): a taxonomic update and review of the literature.Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole.Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation Drug strategies targeting CYP51 in neglected tropical diseases Study on the effect of neem (Azadirachta indica A. juss) leaf extract on the growth of Aspergillus parasiticus and production of aflatoxin by it at different incubation times.Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections.Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.Posaconazole liquid suspension in solid organ transplant recipients previously treated with voriconazole Posaconazole as salvage therapy in a patient with disseminated zygomycosis: case report and review of the literature.Posaconazole: a new broad-spectrum antifungal agent.Minimizing the risk of recurrent or progressive invasive mold infections during stem cell transplantation or further intensive chemotherapy.Invasive fungal infections and antifungal therapies in solid organ transplant recipients.Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma.Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.Clinical pharmacology of antifungal agents in pediatric patients.Long QT Syndrome Leading to Multiple Cardiac Arrests After Posaconazole Administration in an Immune-Compromised Patient with Sepsis: An Unusual Case Report Posaconazole in the management of refractory invasive fungal infections.Posaconazole treatment in Korea: single-center experience over 5 years.Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers.Current options in antifungal pharmacotherapy.Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies. Recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.New and investigational triazole agents for the treatment of invasive fungal infections.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).New generation azole antifungals in clinical investigation.Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Management of drug and food interactions with azole antifungal agents in transplant recipients.Use of posaconazole in the treatment of invasive fungal infections.Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections.Posaconazole: when and how? The clinician's view.Safety of posaconazole.Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications.Posaconazole salvage treatment for invasive fungal infection.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Chemical Composition, Antibacterial and Antifungal Activities of Crude Dittrichia viscosa (L.) Greuter Leaf Extracts.Fusariosis in a Patient with Acute Myeloid Leukemia: A Case Report and Review of the Literature.

P2860

Q28291282-158312C2-9D20-49A1-8DBF-65A2BA340CDB Q33514740-8ABBB77F-DF9D-4175-B225-D7856A20DEC2 Q34020746-6FD365DE-5BF2-45BC-8BDB-AFCAC7F6681D Q34415094-A6F635FA-C7A3-4186-AF27-B54139CB39F3 Q34452574-CE7896B0-48E9-424C-B5E0-C946FB537B8F Q34622554-F5A14ECD-1D85-400A-A5F1-72FFF45C1525 Q34724824-057C134C-D317-4517-B900-83C6907AE062 Q35026481-B25E6D3F-6952-4298-A2D9-07A1CDC8B7C7 Q35647678-4312381E-88AB-42FF-B296-54A41F11A91B Q35732778-1377F9F6-2C1C-4FB6-A5FE-25BFF7937AAD Q36718486-DF838783-263C-4A26-8605-28E8B9E412D4 Q36828159-6F05C2EE-F15E-4EA2-BEE3-35000EB395DD Q36867435-8C4A1627-BC52-45F9-9D8B-BB29491ADEDE Q36872848-A34B7E1E-BBDF-4579-B650-7BFA778B9CD4 Q36917768-D0F19990-D364-46AB-AFAB-D322DD187425 Q36933464-F1FD9400-FD84-42D9-9987-A1259166D09C Q36968140-323DBE01-9073-4D09-9162-642C6B303F16 Q37020761-7BC4E395-1187-46EA-B823-F329C36B3A98 Q37052755-0C89B670-BCE6-4D55-BE40-0ECA9EDC5753 Q37094649-29C78314-CE7B-4A47-A686-926F3F29C26D Q37115829-937C869B-29ED-44BA-A527-9DEF53F24BB8 Q37151326-4D5D1BF7-5304-43AC-B686-735334AECA50 Q37247780-2A1CDD1F-DC96-4153-8AB1-CB485087E9EA Q37344532-C786E91F-7CA4-46C2-9445-4A743A2A3538 Q37364295-819BADCF-7F65-4228-96A7-31FE7AE3B495 Q37404840-9554D19E-D488-4A99-9F70-A7D65B0DA091 Q37469829-C00C23D5-0DF9-4658-A835-CD6DE1EA5ECD Q37579222-EF5C4048-139E-4CE7-9D2C-68015225F4E1 Q37636223-4C49E4E7-64E9-4A0D-9CD9-4AC205AC7D8A Q37688257-AB71AD56-1418-4318-9C41-C353AC9DBB6E Q37775009-F8A26AC8-7DEF-4357-B2D9-25D959810AA6 Q37810083-3676AE8F-5231-4172-91E7-C4B078708BA2 Q37813420-594A944E-462E-4E51-A2A1-AE890DCB4290 Q37901534-C698B0EC-2C6D-4646-BAB5-A54BC9D70A14 Q38077591-38485A15-181E-4AD1-AE01-66581D1E8CC9 Q38193337-2C22CBCF-CED8-4D07-B2AC-8262A29252CC Q38237895-55DC27C7-A87F-49E3-900F-6C3C912AF5CF Q38284468-35C603F5-2631-4E75-80EC-56937CCD1526 Q38700372-9217282B-D867-48B3-AA3A-B9805BA3AAD2 Q38786385-942A78A0-9080-4EC0-8569-95C9E6A51C02

P2860

Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections.

http://www.wikidata.org/entity/Q42686004

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Safety of long-term oral posac ...... ry invasive fungal infections.

@en

Safety of long-term oral posac ...... ry invasive fungal infections.

@nl

type

label

Safety of long-term oral posac ...... ry invasive fungal infections.

@en

Safety of long-term oral posac ...... ry invasive fungal infections.

@nl

prefLabel

Safety of long-term oral posac ...... ry invasive fungal infections.

@en

Safety of long-term oral posac ...... ry invasive fungal infections.

@nl

P1433

Q42686004-1DDD615A-1CB8-44F9-ADBA-32E4661EF6C3

P1476

Q42686004-CAC6D9B5-2F56-4039-A25D-10B320AEBE30

P2093

Q42686004-0A6FF72E-17DC-42C1-BB86-BE4CCE4A7420

Q42686004-1E3FF7AA-07C3-4664-B2FA-4D8CC78DF456

Q42686004-3115BF18-EA38-4FCA-89B9-6BB597E56837

Q42686004-3CBEEC78-164F-4664-A207-D81300998D3D

Q42686004-413036C6-6159-402F-A3E3-F4EF754D5869

Q42686004-43A554BF-59BD-4C8B-85DF-573FCC0C5CBF

Q42686004-44E46226-0943-4DAD-8271-C8B8AC192701

Q42686004-66249957-B3A4-4A91-BB9C-8967C89299AB

Q42686004-68688305-17B8-401F-B7E1-8F019E8E6DB8

Q42686004-9199565E-03E2-4F93-B5B0-49EB75D751D9

P2860

Q42686004-0B887C68-FB9A-46C0-BE57-1A774DDFEDB9

Q42686004-22DC492D-FDBD-4BC9-8D26-218CE7BBB364

Q42686004-33039261-FEBD-445D-824D-92D087DD30B0

Q42686004-34B2803C-63DF-45F4-AD06-850BB0CF476C

Q42686004-5F0CB3B6-5170-4BED-B2F1-02FB33E38297

Q42686004-6808F370-E5E7-4FFD-BABD-3002407F7D31

Q42686004-69327451-F7B7-4F9B-9D33-BDCF2C5930F2

Q42686004-69DFC5A7-C01E-4B76-8B66-2397E3156BB3

Q42686004-8520FC0D-B893-4D39-8D31-FB5FD02338B4

Q42686004-85267AF4-857A-4BAA-B455-9A0D1BFF792D

P304

Q42686004-60BE68F5-C4F6-4E74-9CAC-63009F945D8F

P31

Q42686004-288F86D5-820E-4F4D-A804-869B22FAA963

P356

Q42686004-EB79433E-537D-431B-9312-915D7250FB9D

P407

Q42686004-43049C92-9ACA-48DA-AAF9-B9109C6F6B16

P433

Q42686004-F605E1A5-DFE0-467B-803C-DD210D91B5EF

P478

Q42686004-8A737CA2-E494-4577-BE58-245705036865

P50

Q42686004-1E521036-FF47-4018-A946-AED5BDB45190

Q42686004-FE9726C2-E68B-477F-BE77-D104F3B977F7

P577

Q42686004-CBD8982D-B71C-4B50-A929-9A0FE824153C

P5875

Q42686004-18B19F0E-959A-454A-BFEE-FC159795F439

P698

Q42686004-A62A4C3C-2A8E-4FA2-B4DA-4D3B0ACC00A0

P356

P1433

Clinical Infectious Diseases

P1476

Safety of long-term oral posac ...... ory invasive fungal infections

@en

P2093

Amelia Langston

http://www.w3.org/2001/XMLSchema#string

Ana Beatriz Bustamante

http://www.w3.org/2001/XMLSchema#string

Andrew J Ullmann

http://www.w3.org/2001/XMLSchema#string

Angela Restrepo

http://www.w3.org/2001/XMLSchema#string

Claude Afif

http://www.w3.org/2001/XMLSchema#string

Donald R Graham

http://www.w3.org/2001/XMLSchema#string

Gary Schiller

http://www.w3.org/2001/XMLSchema#string

Issam I Raad

http://www.w3.org/2001/XMLSchema#string

John R Graybill

http://www.w3.org/2001/XMLSchema#string

Lisa Pedicone

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida

In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates

Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.

Caspofungin: the first representative of a new antifungal class.

Review of the safety, tolerability, and drug interactions of the new antifungal agents caspofungin and voriconazole.

Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults

Mortality and cancer incidence among individuals with Down syndrome.

Disposition of posaconazole following single-dose oral administration in healthy subjects.

Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera.

P304

1726-1734

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/504328

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

42

http://www.w3.org/2001/XMLSchema#string

P50

Oliver A Cornely

P577

2006-05-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7075216

http://www.w3.org/2001/XMLSchema#string

P698

16705579

http://www.w3.org/2001/XMLSchema#string